ArticleResearch in pharmaceutical sciences2022
Harmine mitigates cisplatin-induced renal injury in male mice through antioxidant, anti-inflammatory, and anti-apoptosis effects.
Article in Research in pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Mechanistic insights into sitagliptin's action in rat inflammatory bowel disease: involvement of the NO-cGMP-KATP pathway.Research in pharmaceutical sciences · 2026Article
- Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model.Research in pharmaceutical sciences · 2026Article
- Therapeutic potential of harmine in polycystic ovarian syndrome: regulation of TNF-α/IL-6-mediated inflammation, Nrf2/keap-1 signaling, and ovarian steroidogenesis in Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Protective effects of cilostazol against cisplatin-induced hepatorenal toxicity in male mice.Research in pharmaceutical sciences · 2026Article
- Thymoquinone mitigates diclofenac-induced hepatorenal toxicity in male Wistar rats by balancing the redox state and modulating Bax/Bcl-2/caspase-3 apoptotic pathways and NF-κB signaling.Research in pharmaceutical sciences · 2025Article
- Harmine exhibits anti-apoptotic properties and reduces diabetes-induced testicular damage caused by streptozotocin in rats.Clinical and experimental reproductive medicine · 2024Article
- Curcumin supplementation prevents cisplatin-induced nephrotoxicity: a randomized, double-blinded, and placebo-controlled trial.Research in pharmaceutical sciences · 2023Article
- Phytocompounds from Amazonian Plant Species against Acute Kidney Injury: Potential Nephroprotective Effects.Molecules (Basel, Switzerland) · 2023Review
- Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin.Research in pharmaceutical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Cisplatin is a chemotherapeutic drug used to treat cancer, however, causes kidney toxicity. Harmine is a plant-derived alkaloid with a wide range of therapeutic applications. The effects of harmine on the renal side effects of cisplatin in mice were studied in this study. Experimental approach: Forty-eight male BALB/c mice were randomly divided into eight groups (n = 6). They were treated with saline, cisplatin (5.5 mg/kg), harmine (5, 10, and 15 mg/kg/day), cisplatin + harmine (5, 10, and 15 mg/kg/day), respectively. All administrations were done daily and intraperitoneally for 4 days. The criteria related to histology, oxidation, anti-oxidation, inflammation, and apoptosis of renal tissue were evaluated. Findings / Results: There was a significant decrease in total antioxidant capacity of renal tissue, renal corpuscles diameter, and Conclusion and implications: Harmine protected the kidneys against cisplatin-induced damage. Antioxidant, anti-inflammatory, and anti-apoptotic harmine properties were involved in this healing effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.